Related Experiment Videos

Valve replacement for appetite suppressant-induced valvular heart disease

S S Biswas1, C L Donovan, J M Forbess

  • 1Division of Thoracic and Cardiovascular Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

Insights

Valvular heart disease linked to appetite suppressants is a new concern. Prolonged use or combination therapy increases the risk of heart valve damage, even with short-term exposure.

Area of Science:

  • Cardiology
  • Pharmacology
  • Pathology

Background:

  • Valvular heart disease is a newly recognized clinical entity associated with appetite-suppressant medications.
  • The pathological mechanism of valvular injury is not fully understood.
  • Observed valvular abnormalities share similarities with those seen in carcinoid syndrome.

Observation:

  • Clinically significant valvular heart disease is uncommon with short-term (under 3 months) use of appetite suppressants.
  • Extended exposure, higher dosages, and combination drug regimens elevate the risk of valvular pathology.
  • A case report details severe mitral regurgitation in a patient with brief (3 weeks) exposure to fenfluramine and phentermine combination therapy.

Findings:

  • Short-term use of appetite suppressants can lead to severe mitral regurgitation.
  • Combination therapy with fenfluramine and phentermine, even for a short duration, may pose a risk.
  • The study highlights a potential link between specific appetite suppressants and acute valvular dysfunction.

Implications:

  • Further research is needed to elucidate the mechanism of drug-induced valvular injury.
  • Clinical vigilance for valvular heart disease is warranted in patients using appetite suppressants, especially combination therapies.
  • This case underscores the importance of considering medication history in patients presenting with valvular abnormalities.

Related Concept Videos